Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AUPH. Aurinia Pharmaceuticals Inc.’s share was trading at $18.62 as of June 24th. AUPH’s trailing and forward P/E were 8.27 and 23.42 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. AUPH is emerging as a compelling immunology investment as the market continues to undervalue both the durability of its flagship lupus nephritis therapy, LUPKYNIS, and the potential of its expanding pipeline.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
LUPKYNIS, the first FDA-approved oral treatment for active lupus nephritis, has established itself as a leading therapy through strong Phase 3 data demonstrating significantly improved renal response rates, rapid proteinuria reduction, and a favorable safety profile.
The drug benefits from patent protection through 2037, regulatory exclusivity, high physician switching costs, and an entrenched commercial presence among nephrologists and rheumatologists, creating a durable competitive moat. Beyond LUPKYNIS, Aurinia has transformed from a single-product company into a diversified immunology platform through the development of aritinercept, a dual BAFF/APRIL inhibitor targeting a broader spectrum of B-cell activity than existing therapies, and the acquisition of Kezar Life Sciences, which added zetomipzomib, a first-in-class immunoproteasome inhibitor with applications in lupus nephritis and autoimmune hepatitis.
The company is financially strong, reporting $378.8 million in cash and investments, GAAP profitability, 92% gross margins, and positive operating cash flow, allowing it to fund development without dilution risk. Key catalysts include mid-2026 PALIZADE data for zetomipzomib, additional Phase 2 studies for aritinercept, and potential guidance upgrades as LUPKYNIS adoption continues to expand.
The bullish thesis rests on the market’s failure to fully value LUPKYNIS’ long-term growth trajectory, the optionality embedded within the pipeline, and the strategic transformation of the business. Based on a risk-adjusted net present value framework incorporating commercial revenues, pipeline assets, royalties, and cash, the shares are estimated to be worth $24.64, implying approximately 56.7% upside from the current price of $15.72, while downside appears limited by the company’s cash generation, balance sheet strength, and established commercial franchise.
Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive analytics in February 2025, which highlighted the company’s ability to manage regulatory, currency, and COVID-related headwinds while preserving profitability and setting the stage for improved growth. GILD’s stock price has appreciated by approximately 20.14% since our coverage. BioEquity Watch shares a similar view but emphasizes on Aurinia Pharmaceuticals’ undervalued immunology platform, expanding pipeline, and clinical catalysts driving future growth.
Aurinia Pharmaceuticals Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 28 hedge fund portfolios held AUPH at the end of the first quarter which was 33 in the previous quarter. While we acknowledge the risk and potential of AUPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AUPH and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
